All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

IO102-IO103 Plus Pembrolizumab Demonstrates Favorable Activity in PD-L1–High HNSCC and NSCLC

October 29th 2025

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

New Genomic Test Could Spare Some People With Melanoma From Lymph Node Biopsy Surgery

October 29th 2025

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC

October 29th 2025

The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

LEAP-012 Trial of Pembrolizumab/Lenvatinib/TACE to Close Following Missed OS End Point in Unresectable HCC

October 29th 2025

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC

October 29th 2025

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.

Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025

October 29th 2025

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

ICI Use Does Not Significantly Affect EOL Outcomes in HCC

October 29th 2025

Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

FDA Grants Breakthrough Device Designation to PlasmaSure for NMIBC

October 28th 2025

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

Novel Program Aims to Provide Patient-Level Clinical Trial Communication Skills to Hematology/Oncology Fellows

October 28th 2025

Carma L. Bylund, PhD, discussed the findings from a pilot study of a fellowship-level program for clinical trial communication skills.

Improving Immunotherapy Responses by Approaching on Two Fronts

October 28th 2025

Yale Cancer Center researchers publish promising study of dual inhibition of PD1 and macrophage migration inhibitory factor.

Selumetinib Nets EU Approval for Adult NF1-Associated Plexiform Neurofibromas

October 28th 2025

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

Belzutifan-Based Combinations Meet DFS, PFS End Points in Renal Cell Carcinoma

October 28th 2025

Two belzutifan-based combinations met their respective primary efficacy end points of DFS and PFS in the phase 3 LITESPARK-022 and LITESPARK-011 trials.

Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma

October 28th 2025

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer

October 28th 2025

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Emerging Agents and Paradigm Shifts in Gynecologic Cancer: Expert Takeaways From ESMO 2025

October 28th 2025

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

FDA Awards Fast Track Designation to MT-125 for Glioblastoma

October 28th 2025

FDA grants fast track status to MT-125, a first-in-class NMII inhibitor, aiming to bring a novel treatment option to patients with aggressive glioblastoma.

ELI-002 7P Shows Potential to Address Unmet Need in Pancreatic Ductal Adenocarcinoma

October 27th 2025

Specific HLA types were not found to be associated with robust mKRAS-specific T-cell responses after treatment with ELI-002 7P in patients with PDAC.

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma

October 27th 2025

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management

October 27th 2025

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

BiTE-Based Immunotherapy Strategy Could Point the Way to a Breakthrough for Ovarian Cancer Patients

October 27th 2025

Roswell Park-led study reveals benefits of combining adoptive cell therapy with immune checkpoint inhibitors in ovarian cancer.